Universitätsklinikum Erlangen

CAR T-Cell Therapy Induces Remission in Severe Autoimmune Diseases

- A pilot study demonstrates that CAR T-cell therapy can induce long-term remission in severe autoimmune diseases, potentially eliminating the need for continuous drug-based therapy. - The therapy involves a single infusion of CAR T-cells, engineered from the patient's own immune cells, to target and eliminate pathogenic B-lymphocytes. - Clinical trials showed resolution of chronic inflammation in vital organs, joints, and skin, allowing patients to discontinue immunosuppressive drugs like cortisone for several years. - Researchers observed that while B-cells eventually return post-treatment, they are 'naive' and do not trigger the original autoimmune response, suggesting a 'reset' of the immune system.